Update on new biologics for intractable eosinophilic asthma: impact of reslizumab.

Drug Des Devel Ther · 2018 · PMC5951215 · PMID 29780238

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

ACQ scores showed a trend toward better asthma control in the treatment group, and this was significant in the subgroup analysis of patients with nasal polyps.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.